Storm Therapeutics secures £9.2m for clinical stage RNA research

Small molecule therapies designed to inhibit RNA modifying enzymes are the primary focus of Storm Therapeutics, which has raised an estimated £9.2m in new funding. Based at the Babraham Research Campus in Cambridge, the clinical stage biotechnology company reached an estimated post-money valuation of £16.4m following this latest capital injection.

Founded in 2015, Storm Therapeutics develops treatments for cancer, inflammation, viral infections, and central nervous system diseases. The company identifies therapeutic targets from approximately 300 RNA modifying enzymes using a proprietary drug discovery and RNA analytics platform. Its lead candidate, a METTL3 inhibitor known as STC-15, was the first RNA modifying enzyme inhibitor to enter human clinical evaluation.

The latest financial filings for the company report annual revenue of £6.5m and an operating loss of £11m. While LinkedIn data lists 13 staff members, official accounts record an employee headcount of 38.

This £9.2m round (allotted in April 2026) follows a period of high activity for the company. In December 2025, Storm Therapeutics secured two rounds of £8.1m and £4.2m. Earlier in January 2025, the company completed four separate funding allotments totaling £29.7m. Previous activity also includes three rounds in May 2023 totaling £9.1m and a £2.1m round in August 2022.

The company maintains an in house research team and utilizes external contract research organizations, such as Evotec, for discovery activities. Its pipeline includes additional candidates that were scheduled for advancement into IND-track activities following the initial clinical trials of STC-15.